A series of peripheral blood specimens from 37 NSCLC patients, enrolled in the TRIGGER trial, carrying EGFR mutations in their primary tumor, were subjected to CTC preparation by the Veridex CellSearch System and investigated for EGFR mutations by next generation sequencing on the 454 GS Junior platform. Here, EGFR is linked to neoplasm.